A method for treating hypertension and / or preventing or treating heart failure in a mammal receiving anticoagulant therapy, comprising administering to said mammal a) a pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula [(A) (A)] (C) xHO (I) , where A is SN-valeryl-N - {[2 - (1H-tetrazol-5-yl) diphenyl-4-yl] methyl} valine in the form of an anion A is ethyl ester of (2R, 4S) -5-diphenyl- 4-yl-4- (3-carboxypropionylamino) -2-methylpentanoic acid in the form of an anion (Cat) is a cation y represents (i) valsartan or a pharmaceutically acceptable salt thereof (ii) N- (3-carboxy-1-oxopropyl) - (4S) ethyl ester, - (p-phenylphenylmethyl) -4-amino-2H-methylbutanoic acid or (2R, 4S) -5-diphenyl-4-yl-4- (3-carboxypropionylamino) -2-methylpentanoic acid or a pharmaceutically acceptable salt thereof and (iii) a pharmaceutically acceptable carrier. The process according to claim 1, wherein the compound of formula (I) is trisodium [3 - ((1S, 3R) -1-diphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate- (S) -3-methyl -2 - (pentanoyl- {2 "- (tetrazol-5-yl)) diphenyl-4-ylmethyl} amino) butyrate] hemi-pentahydrate.3 The method of claim 1, wherein the anticoagulant treatment comprises the administration of warfarin or its pharmaceutically acceptable salt. 4. The method of claim 1, wherein heart failure is congestive heart failure, left ventricular failure, right ventricular failure, chronic heart failure, severe heart failure, acute heart failure, acute decompensated heart failure1. Способ лечения гипертензии и/или предотвращения или лечения сердечной недостаточности у млекопитающего, получающего терапию антикоагулянтами, включающий введение указанному млекопитающемуa) фармацевтической композиции, включающей терапевтически эффективное количество соединения формулы[(A1)(A2)](C)y·xH2O (I),где A1 является S-N-валерил-N-{[2-(1Н-тетразол-5-ил)дифенил-4-ил]метил}валином в форме анионаA2 является сложным этиловым эфиром (2R,4
